A rare, chronic autoimmune condition called pemphigus vulgaris is characterized by developing skin and mucous membrane blisters. It is considered the most typical variation of the autoimmune blistering illness known as pemphigus. In pemphigus vulgaris, the immune system unintentionally generates antibodies that target desmogleins, a class of proteins necessary for the attachment of skin cells. Blisters develop due to this antibody attack, and skin layers separate. The body can develop blisters anywhere, but the mouth, throat, scalp, face, chest, groyne, and armpits are the most typical locations for them to appear. The rising awareness regarding diseases is expected to drive market growth.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-pemphigus-vulgaris-market
Data Bridge Market Research analyzes that the Pemphigus Vulgaris Market is expected to grow at a CAGR of 8.2% in the forecast period of 2023 to 2030 and is expected to reach USD 677.32 million by 2030. The treatment segment is projected to propel the market growth as they are widely used and prescribed for the first line therapy of the disease. Especially, these treatments have a broad range of applications for research and clinical purposes among others.
Key Findings of the Study
Emerging Treatment Options for Pemphigus Vulgaris
Pemphigus vulgaris is a chronic immune system disorder that affects a small percentage of people. Blisters appear on the skin and in the mouth as a result. Although treatment and diagnosis can help to control, if it causes serious symptoms. Autoantibodies that target the adhesion molecules between keratinocytes cause the persistent, severe autoimmune bullous illness known as pemphigus. The condition must be managed for an average of two to three years.
Treatment with systemic glucocorticoids can save lives in people with pemphigus vulgaris, but it can also have fatal side effects. Before the necessity to provide systemic glucocorticosteroids, a patient with pemphigus vulgaris and myasthenia gravis was treated for almost five years with the cholinomimetic drugs Mestinon (pyridostigmine bromide), Imuran (azathioprine), and a topical corticosteroid gel.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in Million, Volumes in Units, and Pricing in USD
|
|
Segments Covered
|
Diagnosis and Treatment (Diagnosis and Treatment), Population Type (Pediatric, Adults, and Geriatric), End User (Hospitals, Specialty Clinics, Research Institutes, and Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, and Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada, and Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Belgium, Turkey, and Rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, and Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Israel, Egypt, and Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America
|
|
Market Players Covered
|
Sanofi (U.S.), Regeneron Pharmaceuticals Inc. (U.S.), Fresenius Kabi AG (Germany), Boehringer Ingelheim International GmbH (Germany), Johnson & Johnson Services, Inc. (U.S.), RAKSHIT DRUGS PVT. LTD (India), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Celltrion Healthcare Co., Ltd. (South Korea), AbbVie Inc. (U.S.), Novartis AG (Switzerland), Amgen Inc. (U.S.), Merck & Co., Inc. (U.S.), AstraZeneca (U.K.), Teva Pharmaceutical Industries Ltd (Israel), Lilly (U.S.), Zydus Group (India), GSK plc (U.K.) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
The market is segmented into four notable segments on the basis of diagnosis and treatment, population type, end user, and distribution channel.
- Based on diagnosis and treatment, the market is segmented into diagnosis and treatment.
In 2023, the treatment segment of the diagnosis and treatment segment is expected to dominate the market
In 2023, the treatment segment is expected to dominate the market with a market share of 65.55% due to the growing demand and adoption of treatment approaches for patients.
- Based on population type, the market is segmented into pediatric, adults, and geriatric.
In 2023, the adults segment of the population type segment is expected to dominate the market
In 2023, the adults segment is expected to dominate the market with a market share of 62.86% due to the more prevalence in a certain age group.
- Based on end user, the market is segmented into hospitals, specialty clinics, research institutes, and others. In 2023, the hospitals segment is expected to dominate the market with a market share of 49.67% due to the more preferred treatment center by the patients.
- Based on distribution channel, the market is segmented into hospitals pharmacy, retail pharmacy, and online pharmacy. In 2023, the hospitals pharmacy segment is expected to dominate the market with a market share of 49.33% due to a wide range of drug or product availability.
Major Players
Data Bridge Market Research recognizes the following companies as the major pemphigus vulgaris market players in the global pemphigus vulgaris market that include Sanofi (U.S.), Regeneron Pharmaceuticals Inc. (U.S.), Fresenius Kabi AG (Germany), Boehringer Ingelheim International GmbH (Germany), Johnson & Johnson Services, Inc. (U.S.), RAKSHIT DRUGS PVT. LTD (India), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Celltrion Healthcare Co., Ltd. (South Korea), AbbVie Inc. (U.S.), Novartis AG (Switzerland), Amgen Inc. (U.S.), Merck & Co., Inc. (U.S.), AstraZeneca (U.K.), Teva Pharmaceutical Industries Ltd (Israel), Lilly (U.S.), Zydus Group (India), and GSK plc (U.K.) among others.
Market Development
- In June 2023, AbbVie Inc. announced that in patients with previously untreated CLL with co-existing diseases, an R/R CLL, VENCLYXTO/VENCLEXTA (venetoclax)-based combination therapy showed sustained long-term safety and efficacy. At the European Haematology Association (EHA) Annual Congress in Frankfurt, Germany, the findings are being discussed orally.
- In May 2023, Novartis AG announced the clinical trial study titled "Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients with Lupus Nephritis: a 12 Month, Single-arm, and Observational Study in Taiwan Population".
- In January 2023, Merck & Co., Inc. announced the FDA had approved KEYTRUDA, Merck's anti-PD-1 therapy, as a single agent for adjuvant therapy following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a 4 centimeters [cm]), II, or IIIA non-small cell lung cancer (NSCLC).
- In May 2020, Celltrion Healthcare Co., Ltd announced that it had introduced its biotherapeutic medicine Truxima (CTP10), which is identical to rituximab, in Brazil. According to Celltrion, Truxima is the only rituximab-related biotherapeutic therapy made available in Latin America that has also received approval from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). This made it easier for the business to sell its goods in the area.
- In October 2022, Amgen Inc. stated that it is previously announced acquisition of ChemoCentryx, Inc., for USD52 per share in cash, or an approximate USD3.7 billion total merger consideration, was successful. The purchase includes TAVNEOS, a selective complement 5a receptor inhibitor that may be used orally and was given its nod by the FDA in October 2021.
Regional Analysis
Geographically, the countries covered in the global pemphigus vulgaris market report are the U.S., Canada, and Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Belgium, Turkey, and Rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, and Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Israel, Egypt, and Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in the global pemphigus vulgaris market during the forecast period of 2023 to 2030
In 2023, North America is expected to dominate the market owing to the higher level of investments by U.S. manufacturers and the increasing advancement in the treatment options in the U.S. North America will continue to dominate the market in terms of market share and market revenue, and will continue to flourish its dominance during the forecast period. This is due to the growing adoption of advanced technology in this region.
Asia-Pacific is estimated to be the fastest-growing region in the global pemphigus vulgaris market during the forecast period of 2023 to 2030
Asia-Pacific is expected to grow during the forecast period due to the rapid development of medical facilities in emerging economies in this region. In addition, the rising level of healthcare expenditure and increasing per-capita income are expected to propel the market growth.
For more detailed information about the global pemphigus vulgaris market report, click here – https://www.databridgemarketresearch.com/reports/global-pemphigus-vulgaris-market
